A new type of immunotherapy may offer a new hope to cancer patients who do not respond to existing treatments. Scientists at King’s College London have developed an antibody therapy that activates the immune system in a different way, which helps to fight cancer more effectively. This success can be particularly beneficial for patients with aggressive breast and ovarian cancer.

How does this new treatment work? Immunotherapy is a type of treatment that uses its body’s own immune system to attack cancer cells. Unlike chemotherapy or radiation, which can harm healthy cells, immunotherapy only targets cancer. The most common antibodies used in cancer immunotherapy are called IgG, which helps to identify cancer cells and destroy the immune system. However, IGG therapy is not always effective, especially in some patients with HER2 positive breast and ovarian cancer.

Her2 is a protein that is found in some cancer cells that promotes their growth. Current treatment, such as IgG-based drugs, want to block Her2 to slow down the spread of cancer. However, not all patients respond to these treatments, to seek alternative solutions to prominent researchers.

A new antibody: IGE

Dr. The research team at the King’s College London led by Heather Bax discovered the ability of a separate antibody called IGE. Unlike IGG, IGE interacts with various immune cells, activating them in a unique way to fight cancer. The study focused on creating an IGE version of existing IGG therapy and testing their ability to trigger the immune response against HER2 positive cancer cells.

The results were promising. IGE Antibody not only activated immune cells, but also repeated the environment around the tumor. This innings replaced the immune system by pressing (which allows the tumor to grow) to be highly active in attacking cancer cells.

Positive results in animal testing

Researchers tested this new approach in mice in which tumors were resistant to traditional treatments. They found that IGE therapy successfully directed immune cells to attack her2 positive cancer cells and slow the growth of tumors. This suggests that IGE-based treatment can be an effective option for patients who do not benefit from existing treatments.

Dr. Bax explained the importance of this discovery, “About 20 percent of breast and ovarian cancer is Her2-positive. By developing IGE antibodies that targets HER2, we have shown for the first time that they can effectively repeat the immune system to fight cancer. It can provide a new treatment option for patients with cancer.”

What will happen next?

While the study was conducted in mice, the next step is to develop therapy for human use. Researchers believe that IGE therapy may be available in 3 to 5 years, with correct investment and clinical trials.

Professor Sophia Karagianis, a co-author of the study, emphasized the widespread ability to treat, “We found that IGE antibodies continuously activate the immune system to fight cancer in various tumor types. It opens a new limit in cancer treatment and can benefit many patients in the future.”

Dr. from breast cancer Kotrena Teminite, which now funds the study, also highlighted its importance, “This exciting research can lead to new remedies for people with her2 positive breast cancer, which do not respond to existing treatments. Now that we know that treatment works in principle, will help to determine their full potential for further studies patients.”

Future of cancer treatment

When successful, IGE therapy may barely revolutionize cancer by offering more targeted and effective approaches to patients with tumors. The ability of IGE antibodies to re -prepare the immune system makes him a promising candidate for future treatments.

Now get the latest news with health and braking news and top headlines worldwide.